Eli Lilly Raises Prices To Offset Reduced US Demand

Sales recorded by the world's 10th largest pharmaceutical company, Eli Lilly, increased from US$5.3bn in Q209 to US$5.7bn in Q210, a rise of 8.6%. Net profits grew by 16.4% and earnings per share (EPS) rose by 10%. These results were driven mainly by ongoing cost-containment efforts, the favourable impact of foreign exchange rates outside the eurozone and increased international market demand, albeit to a lesser extent.

To read the full article, please choose one of the following options: